{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:05:47Z","timestamp":1783595147477,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":1448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/ajt.14948","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T09:49:13Z","timestamp":1527328153000},"page":"2977-2986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4065-934X","authenticated-orcid":false,"given":"Tracey","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kanellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1111\/ajt.14948_bib1","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA."},{"issue":"17","key":"10.1111\/ajt.14948_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1111\/ajt.14948_bib3","unstructured":"ANZDATA Registry. 39th Report Chapter 8: Transplantation. Australian and New Zealand Dialysis and Transplant Registry, Adelaide, Australia; 2017. http:\/\/www.anzdata.org.au\/. Accessed February 14, 2018."},{"issue":"1","key":"10.1111\/ajt.14948_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/carcin\/bgh291","article-title":"Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients","volume":"26","author":"Fryer","year":"2005","journal-title":"Carcinogenesis."},{"issue":"5","key":"10.1111\/ajt.14948_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1681\/ASN.2009101043","article-title":"Long-term cancer risk of immunosuppressive regimens after kidney transplantation","volume":"21","author":"Gallagher","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"10.1111\/ajt.14948_bib6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14948_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1111\/ajt.14948_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","article-title":"Rapamycin is an effective inhibitor of human renal cancer metastasis","volume":"63","author":"Luan","year":"2003","journal-title":"Kidney Int."},{"issue":"12","key":"10.1111\/ajt.14948_bib9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation."},{"issue":"10","key":"10.1111\/ajt.14948_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"JCO."},{"issue":"7","key":"10.1111\/ajt.14948_bib11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf."},{"issue":"suppl_3","key":"10.1111\/ajt.14948_bib12","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2014renal transplantation","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"10.1111\/ajt.14948_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14948_bib14","unstructured":"Higgins JPT, Green S, (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http:\/\/handbook.cochrane.org\/. Accessed February 14, 2018."},{"key":"10.1111\/ajt.14948_bib15","unstructured":"ANZDATA Registry. 28th Report Chapter 10: Cancer Report. Adelaide, Australia; 2006. http:\/\/www.anzdata.org.au\/. Accessed February 14, 2018."},{"issue":"4","key":"10.1111\/ajt.14948_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials."},{"issue":"5","key":"10.1111\/ajt.14948_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat Med."},{"issue":"9","key":"10.1111\/ajt.14948_bib18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/sim.2050","article-title":"Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes","volume":"24","author":"Smith","year":"2005","journal-title":"Stat Med."},{"issue":"11","key":"10.1111\/ajt.14948_bib19","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"10.1111\/ajt.14948_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1740774507085276","article-title":"A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes","volume":"4","author":"Tudur Smith","year":"2007","journal-title":"Clin Trials."},{"issue":"6","key":"10.1111\/ajt.14948_bib21","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14948_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int."},{"issue":"7","key":"10.1111\/ajt.14948_bib23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14948_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14948_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transpl Int."},{"issue":"9","key":"10.1111\/ajt.14948_bib26","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.14948_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation."},{"issue":"1","key":"10.1111\/ajt.14948_bib28","doi-asserted-by":"crossref","first-page":"e0170246","DOI":"10.1371\/journal.pone.0170246","article-title":"Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS ONE."},{"key":"10.1111\/ajt.14948_bib29","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ."},{"issue":"9","key":"10.1111\/ajt.14948_bib30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.14948_bib31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int."},{"issue":"9103","key":"10.1111\/ajt.14948_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet."},{"issue":"12","key":"10.1111\/ajt.14948_bib33","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14948_bib34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol."},{"issue":"2","key":"10.1111\/ajt.14948_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/TP.0b013e31825475a3","article-title":"Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial","volume":"94","author":"Clayton","year":"2012","journal-title":"Transplantation."},{"issue":"6","key":"10.1111\/ajt.14948_bib36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/ki.2013.458","article-title":"Malignancy-related mortality following kidney transplantation is common","volume":"85","author":"Farrugia","year":"2014","journal-title":"Kidney Int."},{"issue":"10","key":"10.1111\/ajt.14948_bib37","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2215\/CJN.00190116","article-title":"Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients","volume":"11","author":"Badve","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"10.1111\/ajt.14948_bib38","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1097\/TP.0000000000001793","article-title":"Patient preferences for outcomes after kidney transplantation: a best-worst scaling survey","volume":"101","author":"Howell","year":"2017","journal-title":"Transplantation."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14948\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:21:45Z","timestamp":1761628905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522098094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1600613522098094"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14948","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733315438.793556288","asserted-by":"object"}]},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}